Browse SEMA7A

Summary
SymbolSEMA7A
Namesemaphorin 7A, GPI membrane anchor (John Milton Hagen blood group)
Aliases H-Sema-L; CD108; John Milton Hagen blood group; H-Sema K1; sema domain, immunoglobulin domain (Ig), and GPI ......
Chromosomal Location15q22.3-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Lipid-anchor, GPI-anchor Extracellular side Note=Detected in a punctate pattern on the cell membrane of basal and supra-basal skin keratinocytes.
Domain PF13895 Immunoglobulin domain
PF01437 Plexin repeat
PF01403 Sema domain
Function

Plays an important role in integrin-mediated signaling and functions both in regulating cell migration and immune responses. Promotes formation of focal adhesion complexes, activation of the protein kinase PTK2/FAK1 and subsequent phosphorylation of MAPK1 and MAPK3. Promotes production of proinflammatory cytokines by monocytes and macrophages. Plays an important role in modulating inflammation and T-cell-mediated immune responses. Promotes axon growth in the embryonic olfactory bulb. Promotes attachment, spreading and dendrite outgrowth in melanocytes.

> Gene Ontology
 
Biological Process GO:0001503 ossification
GO:0001558 regulation of cell growth
GO:0001649 osteoblast differentiation
GO:0001667 ameboidal-type cell migration
GO:0001755 neural crest cell migration
GO:0001819 positive regulation of cytokine production
GO:0002367 cytokine production involved in immune response
GO:0002440 production of molecular mediator of immune response
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002702 positive regulation of production of molecular mediator of immune response
GO:0002718 regulation of cytokine production involved in immune response
GO:0002720 positive regulation of cytokine production involved in immune response
GO:0007229 integrin-mediated signaling pathway
GO:0007409 axonogenesis
GO:0008361 regulation of cell size
GO:0010720 positive regulation of cell development
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010770 positive regulation of cell morphogenesis involved in differentiation
GO:0010934 macrophage cytokine production
GO:0010935 regulation of macrophage cytokine production
GO:0010975 regulation of neuron projection development
GO:0010976 positive regulation of neuron projection development
GO:0014031 mesenchymal cell development
GO:0014032 neural crest cell development
GO:0014033 neural crest cell differentiation
GO:0016049 cell growth
GO:0021537 telencephalon development
GO:0021988 olfactory lobe development
GO:0022604 regulation of cell morphogenesis
GO:0030307 positive regulation of cell growth
GO:0030335 positive regulation of cell migration
GO:0030516 regulation of axon extension
GO:0030900 forebrain development
GO:0031346 positive regulation of cell projection organization
GO:0032535 regulation of cellular component size
GO:0040017 positive regulation of locomotion
GO:0043410 positive regulation of MAPK cascade
GO:0045666 positive regulation of neuron differentiation
GO:0045773 positive regulation of axon extension
GO:0045927 positive regulation of growth
GO:0048588 developmental cell growth
GO:0048638 regulation of developmental growth
GO:0048639 positive regulation of developmental growth
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048675 axon extension
GO:0048762 mesenchymal cell differentiation
GO:0048863 stem cell differentiation
GO:0048864 stem cell development
GO:0050727 regulation of inflammatory response
GO:0050769 positive regulation of neurogenesis
GO:0050770 regulation of axonogenesis
GO:0050772 positive regulation of axonogenesis
GO:0051272 positive regulation of cellular component movement
GO:0051962 positive regulation of nervous system development
GO:0060485 mesenchyme development
GO:0060560 developmental growth involved in morphogenesis
GO:0060907 positive regulation of macrophage cytokine production
GO:0061081 positive regulation of myeloid leukocyte cytokine production involved in immune response
GO:0061082 myeloid leukocyte cytokine production
GO:0061387 regulation of extent of cell growth
GO:0061564 axon development
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0090066 regulation of anatomical structure size
GO:1990138 neuron projection extension
GO:2000147 positive regulation of cell motility
Molecular Function GO:0005178 integrin binding
GO:0038191 neuropilin binding
GO:0050839 cell adhesion molecule binding
Cellular Component GO:0009897 external side of plasma membrane
GO:0031225 anchored component of membrane
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04360 Axon guidance
Reactome R-HSA-422475: Axon guidance
R-HSA-1266738: Developmental Biology
R-HSA-416700: Other semaphorin interactions
R-HSA-373755: Semaphorin interactions
Summary
SymbolSEMA7A
Namesemaphorin 7A, GPI membrane anchor (John Milton Hagen blood group)
Aliases H-Sema-L; CD108; John Milton Hagen blood group; H-Sema K1; sema domain, immunoglobulin domain (Ig), and GPI ......
Chromosomal Location15q22.3-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SEMA7A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSEMA7A
Namesemaphorin 7A, GPI membrane anchor (John Milton Hagen blood group)
Aliases H-Sema-L; CD108; John Milton Hagen blood group; H-Sema K1; sema domain, immunoglobulin domain (Ig), and GPI ......
Chromosomal Location15q22.3-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SEMA7A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen Total # shRNA with >= 4-fold: 2 Resistant to T-cell proliferation
Summary
SymbolSEMA7A
Namesemaphorin 7A, GPI membrane anchor (John Milton Hagen blood group)
Aliases H-Sema-L; CD108; John Milton Hagen blood group; H-Sema K1; sema domain, immunoglobulin domain (Ig), and GPI ......
Chromosomal Location15q22.3-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SEMA7A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.5450.376
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0490.979
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.9880.521
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.1180.0241
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.0450.535
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.2060.587
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.6660.252
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2370.866
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.6750.274
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.0810.14
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4770.172
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0880.583
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SEMA7A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSEMA7A
Namesemaphorin 7A, GPI membrane anchor (John Milton Hagen blood group)
Aliases H-Sema-L; CD108; John Milton Hagen blood group; H-Sema K1; sema domain, immunoglobulin domain (Ig), and GPI ......
Chromosomal Location15q22.3-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SEMA7A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSEMA7A
Namesemaphorin 7A, GPI membrane anchor (John Milton Hagen blood group)
Aliases H-Sema-L; CD108; John Milton Hagen blood group; H-Sema K1; sema domain, immunoglobulin domain (Ig), and GPI ......
Chromosomal Location15q22.3-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SEMA7A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SEMA7A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSEMA7A
Namesemaphorin 7A, GPI membrane anchor (John Milton Hagen blood group)
Aliases H-Sema-L; CD108; John Milton Hagen blood group; H-Sema K1; sema domain, immunoglobulin domain (Ig), and GPI ......
Chromosomal Location15q22.3-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SEMA7A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSEMA7A
Namesemaphorin 7A, GPI membrane anchor (John Milton Hagen blood group)
Aliases H-Sema-L; CD108; John Milton Hagen blood group; H-Sema K1; sema domain, immunoglobulin domain (Ig), and GPI ......
Chromosomal Location15q22.3-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SEMA7A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSEMA7A
Namesemaphorin 7A, GPI membrane anchor (John Milton Hagen blood group)
Aliases H-Sema-L; CD108; John Milton Hagen blood group; H-Sema K1; sema domain, immunoglobulin domain (Ig), and GPI ......
Chromosomal Location15q22.3-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SEMA7A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSEMA7A
Namesemaphorin 7A, GPI membrane anchor (John Milton Hagen blood group)
Aliases H-Sema-L; CD108; John Milton Hagen blood group; H-Sema K1; sema domain, immunoglobulin domain (Ig), and GPI ......
Chromosomal Location15q22.3-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SEMA7A collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.